NCT06997068 2026-04-03
Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population
Mayo Clinic
Phase 2 Recruiting
Mayo Clinic
University of Utah
Dana-Farber Cancer Institute
VA Office of Research and Development
National Health Research Institutes, Taiwan
Fox Chase Cancer Center
Memorial Sloan Kettering Cancer Center